MOUNTAIN VIEW, Calif., April 28, 2011 /PRNewswire/ -- MAP Pharmaceuticals, Inc. (Nasdaq: MAPP) today announced that the Company will participate in the following investor conferences in May:
Deutsche Bank 36th Annual Healthcare Conference | |
Tuesday, May 3, at 11:20 a.m. ET in Boston | |
Bank of America Merrill Lynch Healthcare Conference | |
Tuesday, May 10, at 5:00 p.m. PT in Las Vegas | |
UBS Global Specialty Pharmaceuticals Conference | |
Tuesday, May 24, at 1:00 p.m. BT in London | |
A live webcast of each event will be available on the Investor Relations section of MAP Pharmaceuticals’ website at http://www.mappharma.com. A replay also will be available within 24 hours for seven days following the presentation.
About MAP Pharmaceuticals
MAP Pharmaceuticals is an emerging biopharmaceutical company focused on developing and commercializing new therapies to address undermet patient needs in neurology. The Company is developing LEVADEX, an orally inhaled investigational drug for the acute treatment of migraine. The Company has reported positive results from its Phase 3 trial of LEVADEX and has entered into a collaboration agreement with Allergan, Inc. to co-promote LEVADEX to neurologists and pain specialists in the U.S. MAP Pharmaceuticals also applies its proprietary drug particle and inhalation technologies to generate new pipeline opportunities by enhancing the therapeutic benefits of proven drugs, while minimizing risk by capitalizing on their known safety, efficacy and commercialization history. Additional information about MAP Pharmaceuticals can be found at http://www.mappharma.com
CONTACTS: | ||
Lisa Borland | ||
MAP Pharmaceuticals, Inc. | ||
(650) 386-3122 | ||
lborland@mappharma.com | ||
SOURCE MAP Pharmaceuticals, Inc.
